Taysha Gene Therapies, Inc. (TSHA)
NASDAQ: TSHA · Real-Time Price · USD
6.40
0.00 (0.00%)
At close: Apr 24, 2026, 4:00 PM EDT
6.44
+0.04 (0.63%)
After-hours: Apr 24, 2026, 5:50 PM EDT
Taysha Gene Therapies Employees
Taysha Gene Therapies had 99 employees as of December 31, 2025. The number of employees increased by 26 or 35.62% compared to the previous year.
Employees
99
Change (1Y)
26
Growth (1Y)
35.62%
Revenue / Employee
$98,717
Profits / Employee
-$1,100,960
Market Cap
1.84B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 99 | 26 | 35.62% |
| Dec 31, 2024 | 73 | 21 | 40.38% |
| Dec 31, 2023 | 52 | -13 | -20.00% |
| Dec 31, 2022 | 65 | -113 | -63.48% |
| Dec 31, 2021 | 178 | 140 | 368.42% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Recursion Pharmaceuticals | 600 |
| Galapagos NV | 558 |
| Vericel | 398 |
| Nurix Therapeutics | 317 |
| Syndax Pharmaceuticals | 298 |
| Harmony Biosciences Holdings | 293 |
| Innoviva | 159 |
| Pharvaris | 129 |
TSHA News
- 22 days ago - Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 5 weeks ago - Taysha Gene Therapies Reports Full-Year 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 6 weeks ago - Taysha Gene Therapies to Release Full-Year 2025 Financial Results and Host Conference Call and Webcast on March 19 - GlobeNewsWire
- 3 months ago - These 20 stocks are strong choices for momentum investors - Market Watch
- 3 months ago - Taysha Gene Therapies Announces Progress Across TSHA-102 Pivotal Gene Therapy Program in Rett Syndrome - GlobeNewsWire
- 6 months ago - Taysha Gene Therapies Reports Third Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 6 months ago - Taysha Gene Therapies to Release Third Quarter 2025 Financial Results and Host Conference Call and Webcast on November 4 - GlobeNewsWire
- 6 months ago - Taysha Gene Therapies Regains Full Rights to Lead TSHA-102 Program in Clinical Evaluation for the Treatment of Rett Syndrome - GlobeNewsWire